Semaglutide: How It Works, Results & Side Effects

If you have been handed a prescription for semaglutide — sold as Ozempic, Rybelsus, or Wegovy — you probably have a lot of questions. What is it actually doing in your body? How much weight can you really expect to lose? Is it safe? And the question almost nobody answers honestly: what happens when you stop? This guide walks through what the published research and the official FDA label actually say, in plain language.

The short version: semaglutide is a genuinely well-studied, FDA-approved medicine with strong randomized-trial evidence behind it. It is not a fad. But it is also prescription-only, it needs careful dose titration to keep side effects manageable, and for most people it is an ongoing therapy rather than a quick course. Let's go through each of those honestly.

What semaglutide is and how it works

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after you eat. It tells your pancreas to release insulin when blood sugar is high, signals your brain that you are full, and slows down how fast your stomach empties¹. Semaglutide is a long-acting molecule designed to mimic that hormone and keep those signals switched on.

In practical terms, that means three things happen. Your blood sugar control improves, which is why semaglutide is approved for type 2 diabetes (and sold as Ozempic for that use). Your appetite goes down and you feel full sooner, which is why it produces weight loss (and is sold as Wegovy for that use — the same molecule under a different label). And because it slows stomach emptying, you may feel queasy or full quickly — the same mechanism that helps you eat less is also the source of the most common side effects¹. A recent authoritative review of the whole GLP-1 class lays out this benefit-and-tolerability balance clearly².

What the weight-loss trials show

The headline weight-loss evidence comes from a trial called STEP 1. In this 68-week randomized study of adults with overweight or obesity (without diabetes), once-weekly semaglutide 2.4 mg produced a large average reduction in body weight compared with placebo — the registration trial behind Wegovy³. This was a high-quality, placebo-controlled trial, not marketing.

The weight loss is real and substantial for many people, but it is an average — individual results vary, and the medicine works alongside diet and activity changes, not instead of them. We go deeper into the numbers and the dosing in Semaglutide Dosing & Side Effects.

What it does for blood sugar and the heart

Semaglutide first earned approval for type 2 diabetes, and that evidence base is large. In the SUSTAIN-6 cardiovascular outcomes trial, injectable semaglutide reduced the risk of major adverse cardiovascular events compared with placebo in people with type 2 diabetes, on top of lowering blood sugar and weight⁴. Head-to-head against another GLP-1 medicine, semaglutide produced greater reductions in HbA1c and body weight⁵.

Even more striking is the SELECT trial. It studied adults with overweight or obesity and existing heart disease but without diabetes, and found that semaglutide 2.4 mg reduced major cardiovascular events — a benefit that goes beyond weight loss alone⁶. That is a meaningful finding, because it suggests the medicine does something for cardiovascular risk directly, not just as a side effect of losing weight.

Dosing: why you start low and go slow

You do not start at the full dose. The FDA prescribing information for Wegovy describes a step-up schedule — starting at 0.25 mg once weekly and increasing every four weeks through 0.5, 1.0, and 1.7 mg up to the 2.4 mg maintenance dose⁷. Ozempic, used for type 2 diabetes, titrates similarly from 0.25 mg up to 1.0 or 2.0 mg weekly⁸. The STEP 1 trial used this same gradual 16-week escalation⁹.

The reason for the slow climb is tolerability. Going straight to a high dose causes far more nausea and vomiting; titrating gives your gut time to adjust. This is not optional fine print — it is the core of using semaglutide well, and we cover it in detail in Semaglutide Dosing & Side Effects.

The side effects, honestly

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. A pooled analysis across the SUSTAIN diabetes trials characterized this profile and, importantly, found that weight loss occurred even in people who did not have GI side effects — so the queasiness is not the "engine" of the weight loss¹⁰. For most people these symptoms are worst early and during dose increases, and they ease over time.

The FDA label also carries a boxed warning about thyroid C-cell tumors (based on rodent studies) and lists contraindications, including a personal or family history of medullary thyroid carcinoma⁷. This is exactly why semaglutide is prescription-only: a clinician needs to screen you, choose the right dose, and monitor you. One quieter trade-off worth planning for is body composition: roughly a quarter to a third of the weight lost is lean mass, which is normal for any large weight loss but worth protecting with protein and resistance training — see will semaglutide make you lose muscle?. Encouragingly, a pooled SUSTAIN analysis showed that a meaningful share of patients reached their blood-sugar target without weight gain, low blood sugar, or GI side effects — the goal is a good balance, not white-knuckling through symptoms¹¹.

Oral or injectable?

Semaglutide comes as a once-weekly injection (Ozempic, Wegovy) and as a daily tablet (Rybelsus). The tablet has its own evidence base — the PIONEER trial program established that oral semaglutide lowers blood sugar effectively and has a reassuring cardiovascular safety profile¹². There are real differences in convenience, dosing rules, and the doses studied. We compare them side by side in Oral vs Injectable Semaglutide, and ask whether the Rybelsus pill actually works for weight loss in Rybelsus (Oral Semaglutide): Does the Pill Work for Weight Loss?.

The part most people miss: it is usually ongoing

Here is the honest reality that marketing tends to skip. Obesity and type 2 diabetes are chronic conditions, and semaglutide manages them rather than curing them. In the STEP 1 trial extension, when people stopped semaglutide they regained roughly two-thirds of the weight they had lost over the following year, and the improvements in blood pressure and other markers reversed too¹³. The STEP 4 trial showed the flip side: people who kept taking it continued to lose or maintain weight, while those switched to placebo regained it¹⁴.

That does not mean you can never stop — that is a conversation for you and your clinician. But it does mean you should go in expecting an ongoing therapy, not a 12-week fix. We unpack the stopping question in What Happens If You Stop Semaglutide?.

The honest bottom line

Semaglutide is one of the most thoroughly studied weight and metabolic medicines available, with real, placebo-controlled evidence for weight loss (STEP 1), blood-sugar control (SUSTAIN), and even cardiovascular risk reduction (SELECT). At the same time, it is prescription-only for good reasons, it requires patient dose titration to keep side effects tolerable, and it generally needs to be continued to hold onto its benefits. If you understand those trade-offs going in, you can make a genuinely informed decision with your clinician. For our independent look at semaglutide options, see our best semaglutide guide.